{"id":"anti-tnf-meth","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection (including serious infections)"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Bone marrow suppression"},{"rate":null,"effect":"Nausea and gastrointestinal effects"}]},"_chembl":{"chemblId":"CHEMBL3897557","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Anti-TNF agents (such as monoclonal antibodies or receptor antagonists) neutralize TNF-α, a key pro-inflammatory cytokine, thereby dampening excessive immune responses. Methotrexate acts as a disease-modifying antirheumatic drug (DMARD) by inhibiting folate metabolism and reducing proliferation of activated lymphocytes. The combination leverages complementary mechanisms to achieve enhanced immunosuppression in inflammatory and autoimmune conditions.","oneSentence":"This combination therapy blocks tumor necrosis factor (TNF) to suppress inflammatory immune responses while methotrexate inhibits dihydrofolate reductase to reduce cell proliferation and immune activation.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:01:50.127Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Other TNF-responsive inflammatory conditions"}]},"trialDetails":[{"nctId":"NCT01724268","phase":"PHASE3","title":"Corticosteroids and Anti TNF in Methotrexate Inadequate Responder Rheumatoid Arthritis Patient","status":"UNKNOWN","sponsor":"Hamad Medical Corporation","startDate":"2012-05","conditions":"RHEUMATOID ARTHRITIS","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":64,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Anti TNF + Meth","genericName":"Anti TNF + Meth","companyName":"Hamad Medical Corporation","companyId":"hamad-medical-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination therapy blocks tumor necrosis factor (TNF) to suppress inflammatory immune responses while methotrexate inhibits dihydrofolate reductase to reduce cell proliferation and immune activation. Used for Rheumatoid arthritis, Other TNF-responsive inflammatory conditions.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}